Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTKLPHO)

DTT Name Neonatal Fc receptor (FCGRT)
Synonyms Neonatal FcR; MHC class I family-like Fc receptor; IgG Fc fragment receptor transporter, alpha chain; FcRn; FCGRT
Gene Name FCGRT
DTT Type
Clinical trial target
 [1]
BioChemical Class
Immunoglobulin
UniProt ID
FCGRN_HUMAN
TTD ID
T06020
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLS
YNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCE
LGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLF
SCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGL
AAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLV
VGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNV
IPATA
Function Binds to the Fc region of monomericimmunoglobulins gamma. Mediates the uptake of IgG from milk. Possible role in transfer of immunoglobulin G from mother to fetus.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Efgartigimod alfa DM2M93X Myasthenia gravis 8C6Y Approved [2]
------------------------------------------------------------------------------------
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARGX-113 DM180DM Myasthenia gravis 8C6Y Phase 3 [3]
Batoclimab DMYPMR8 Myasthenia gravis 8C6Y Phase 3 [4]
Nipocalimab? DM0DYAX Chronic inflammatory demyelinating polyneuropathy 8C01.3 Phase 3 [5]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
SYN-1327 DMFNR75 Discovery agent N.A. Investigative [1]
------------------------------------------------------------------------------------

References

1 Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem. 2008 Jun 15;16(12):6394-405.
2 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761195.
3 Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673.
4 Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2023 Jan;30(1):195-203.
5 New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia. Transfus Med Rev. 2022 Oct;36(4):175-180.